Surgical Science (Q3 initial take): Decent sales, poor margins - Redeye

Redeye provides its initial take on Surgical Science’s Q3 2025 report, which came in slightly below our top-line projection and missed our profitability estimates. Despite disappointing profitability, we believe this quarter was a reassuring move in the right direction after soft Q2 figures. Demand outlook for the seasonally strong fourth quarter appears to be solid, boding well for continued growth.

Länk till analysen i sin helhet: https://www.redeye.se/research/1138695/surgical-science-q3-initial-take-decent-sales-poor-margins?utm_source=finwire&utm_medium=RSS